These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 20140782)
21. [Molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria: a role of NKG2D-medicated immunity]. Kawaguchi T Rinsho Ketsueki; 2010 Aug; 51(8):664-71. PubMed ID: 20805673 [No Abstract] [Full Text] [Related]
22. Eculizumab in paroxysmal nocturnal hemoglobinuria. Kathula SK N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17192547 [No Abstract] [Full Text] [Related]
23. Paroxysmal nocturnal haemoglobulinuria. A case with a positive direct antiglobulin test and good response to corticosteroids. Stojcevski T; Nedelkoski J Acta Med Iugosl; 1970; 24(4):377-82. PubMed ID: 5314263 [No Abstract] [Full Text] [Related]
24. Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab. van Bijnen ST; Vermeer H; Mourisse JM; de Witte T; van Swieten HA; Muus P Eur J Haematol; 2011 Oct; 87(4):376-8. PubMed ID: 21623921 [No Abstract] [Full Text] [Related]
26. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria. Guasch A Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585 [No Abstract] [Full Text] [Related]
27. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Emadi A; Brodsky RA Am J Hematol; 2009 Oct; 84(10):699-701. PubMed ID: 19705437 [No Abstract] [Full Text] [Related]
28. Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Hill A Clin Adv Hematol Oncol; 2005 Nov; 3(11):849-50. PubMed ID: 16491626 [No Abstract] [Full Text] [Related]
29. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria. Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890 [No Abstract] [Full Text] [Related]
30. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992 [TBL] [Abstract][Full Text] [Related]
31. Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure. Kelly RJ; Hill A; Arnold LM; Khursigara G; Kanagasundaram NS; Hillmen P Leuk Res; 2011 Apr; 35(4):560-2. PubMed ID: 21145109 [No Abstract] [Full Text] [Related]
33. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Nishimura JI; Ando K; Masuko M; Noji H; Ito Y; Mayer J; Griskevicius L; Bucher C; Müllershausen F; Gergely P; Rozenberg I; Schubart A; Chawla R; Rondeau JM; Roguska M; Splawski I; Keating MT; Johnson L; Danekula R; Bagger M; Watanabe Y; Haraldsson B; Kanakura Y Haematologica; 2022 Jun; 107(6):1483-1488. PubMed ID: 35263983 [No Abstract] [Full Text] [Related]
34. [Paroxysmal nocturnal hemoglobinuria]. Geffray L Rev Med Interne; 2008 Nov; 29(11):957-61. PubMed ID: 18801601 [No Abstract] [Full Text] [Related]
35. Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008. Haspel RL; Hillmen P Hematology Am Soc Hematol Educ Program; 2008; ():35. PubMed ID: 19074053 [No Abstract] [Full Text] [Related]
36. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. Risitano AM; Notaro R; Luzzatto L; Hill A; Kelly R; Hillmen P N Engl J Med; 2010 Dec; 363(23):2270-2. PubMed ID: 21121856 [No Abstract] [Full Text] [Related]
37. [Rare case of a pregnancy in a woman with paroxysmal nocturnal hemoglobinuria. Case report]. Horányi D; Várkonyi A; Nagy GR; Bodó I; Masszi T Orv Hetil; 2016 Jun; 157(23):916-8; quiz 919-20. PubMed ID: 27233835 [TBL] [Abstract][Full Text] [Related]
38. [Progress in the management of paroxysmal nocturnal hemoglobinuria by eculizumab]. Nakakuma H Rinsho Ketsueki; 2011 Aug; 52(8):633-44. PubMed ID: 21897069 [No Abstract] [Full Text] [Related]
39. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220 [TBL] [Abstract][Full Text] [Related]